Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile6 entries
2026
Medical-assistant workload allegations
Current and former Philippines-based medical assistants alleged that performance targets became exceptionally demanding, with reported workloads exceeding 65 queries per day in some cases and increased dependence on AI.
2025
AI chatbot prompts clinical-governance concerns
Professional bodies raised concerns after Eucalyptus introduced an AI chatbot into weight-loss services, focusing on the safety and appropriateness of automation in medical care.
2025
Eating-disorder groups criticize weight-loss marketing
Peak eating-disorder advocacy organizations expressed concern that aggressive GLP-1 marketing, including social-media activity and a Juniper Black Friday sale, could target people who did not require medication.
2024
Questions over advertising and editorial boundaries
Media reporting and ABC's Media Watch examined whether television segments and other coverage promoting Eucalyptus services clearly separated editorial material from advertising.
2023
Scrutiny of online GLP-1 prescribing
The RACGP questioned whether remote questionnaires supplied adequate clinical assessment for prescribing GLP-1 receptor agonists, while the TGA warned telehealth companies about advertising prescription-only medicines directly to consumers.
2023
Compounded semaglutide controversy
During GLP-1 shortages, Eucalyptus worked with compounding pharmacies to provide compounded semaglutide. Pharmaceutical manufacturers and regulators criticized the practice, followed by an Australian ban on pharmacy compounding of GLP-1 drugs from October 2024.